5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
December 2023 in “Journal of clinical medicine” Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
April 2017 in “Journal of Investigative Dermatology” Fisetin may help treat psoriasis and reduce skin inflammation.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
54 citations
,
June 2023 in “International Journal of Molecular Sciences” Myricetin shows promise as an anticancer agent by reducing inflammation and enhancing drug effectiveness.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.